289 related articles for article (PubMed ID: 19602929)
1. Clinical utility of progesterone receptor modulators and their effect on the endometrium.
Spitz IM
Curr Opin Obstet Gynecol; 2009 Aug; 21(4):318-24. PubMed ID: 19602929
[TBL] [Abstract][Full Text] [Related]
2. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata.
Williams AR; Critchley HO; Osei J; Ingamells S; Cameron IT; Han C; Chwalisz K
Hum Reprod; 2007 Jun; 22(6):1696-704. PubMed ID: 17339234
[TBL] [Abstract][Full Text] [Related]
3. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth.
Yoshida S; Ohara N; Xu Q; Chen W; Wang J; Nakabayashi K; Sasaki H; Morikawa A; Maruo T
Semin Reprod Med; 2010 May; 28(3):260-73. PubMed ID: 20414849
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
[TBL] [Abstract][Full Text] [Related]
5. Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids.
Talaulikar VS; Manyonda I
Eur J Obstet Gynecol Reprod Biol; 2012 Dec; 165(2):135-40. PubMed ID: 22901974
[TBL] [Abstract][Full Text] [Related]
6. Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator.
Ioffe OB; Zaino RJ; Mutter GL
Mod Pathol; 2009 Mar; 22(3):450-9. PubMed ID: 19136935
[TBL] [Abstract][Full Text] [Related]
7. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Williams AR; Bergeron C; Barlow DH; Ferenczy A
Int J Gynecol Pathol; 2012 Nov; 31(6):556-69. PubMed ID: 23018219
[TBL] [Abstract][Full Text] [Related]
8. RU486: pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri.
Murphy AA; Castellano PZ
Curr Opin Obstet Gynecol; 1994 Jun; 6(3):269-78. PubMed ID: 8038415
[TBL] [Abstract][Full Text] [Related]
9. Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata.
Eisinger SH; Fiscella J; Bonfiglio T; Meldrum S; Fiscella K
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):215-8. PubMed ID: 19586708
[TBL] [Abstract][Full Text] [Related]
10. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century.
Spitz IM
Contraception; 2010 Nov; 82(5):442-52. PubMed ID: 20933118
[TBL] [Abstract][Full Text] [Related]
11. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis.
Chwalisz K; Perez MC; Demanno D; Winkel C; Schubert G; Elger W
Endocr Rev; 2005 May; 26(3):423-38. PubMed ID: 15857972
[TBL] [Abstract][Full Text] [Related]
12. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology].
Brazert M; Korman MP; Pawelczyk LA
Ginekol Pol; 2013 Sep; 84(9):794-800. PubMed ID: 24191519
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of uterine fibroids with ulipristal acetate ☆.
Donnez J; Vázquez F; Tomaszewski J; Nouri K; Bouchard P; Fauser BC; Barlow DH; Palacios S; Donnez O; Bestel E; Osterloh I; Loumaye E;
Fertil Steril; 2014 Jun; 101(6):1565-73.e1-18. PubMed ID: 24630081
[TBL] [Abstract][Full Text] [Related]
14. The spectrum of endometrial pathology induced by progesterone receptor modulators.
Mutter GL; Bergeron C; Deligdisch L; Ferenczy A; Glant M; Merino M; Williams AR; Blithe DL
Mod Pathol; 2008 May; 21(5):591-8. PubMed ID: 18246050
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata.
Chwalisz K; DeManno D; Garg R; Larsen L; Mattia-Goldberg C; Stickler T
Semin Reprod Med; 2004 May; 22(2):113-9. PubMed ID: 15164306
[TBL] [Abstract][Full Text] [Related]
16. Histomorphological changes in endometriosis in a patient treated with ulipristal: A case report.
Bateman J; Bougie O; Singh S; Islam S
Pathol Res Pract; 2017 Jan; 213(1):79-81. PubMed ID: 27914766
[TBL] [Abstract][Full Text] [Related]
17. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety.
Bouchard P; Chabbert-Buffet N; Fauser BC
Fertil Steril; 2011 Nov; 96(5):1175-89. PubMed ID: 21944187
[TBL] [Abstract][Full Text] [Related]
18. Progesterone antagonists and progesterone receptor modulators.
Spitz IM
Expert Opin Investig Drugs; 2003 Oct; 12(10):1693-707. PubMed ID: 14519088
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Molecular Changes in Endometrium Associated With Chronic Use of Progesterone Receptor Modulators: Ulipristal Acetate Versus Mifepristone.
Kannan A; Bhurke A; Sitruk-Ware R; Lalitkumar PG; Gemzell-Danielsson K; Williams ARW; Taylor RN; Bagchi MK; Bagchi IC
Reprod Sci; 2018 Mar; 25(3):320-328. PubMed ID: 29241443
[TBL] [Abstract][Full Text] [Related]
20. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial.
Bagaria M; Suneja A; Vaid NB; Guleria K; Mishra K
Aust N Z J Obstet Gynaecol; 2009 Feb; 49(1):77-83. PubMed ID: 19281585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
